Seattle Genetics, Inc. Equity-NMS: SGEN

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$228.9

1Y :

10.41%

5Y :

225.04%

What is the share price of Seattle Genetics, Inc. today?

Seattle Genetics, Inc. (SGEN) share price as of November 21, 2024, is $228.74. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Seattle Genetics, Inc.?

Yes, Indian Investors can invest in the Seattle Genetics, Inc. (SGEN) Share by opening an international trading account with Angel One.

How can I purchase Seattle Genetics, Inc. shares in India?

Purchasing Seattle Genetics, Inc. (SGEN) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Seattle Genetics, Inc. (SGEN) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Seattle Genetics, Inc.?

Yes, you can purchase fractional shares of Seattle Genetics, Inc. (SGEN) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Seattle Genetics, Inc.?

The market capitalization of Seattle Genetics, Inc. on November 21, 2024, is $0.

In which sector Seattle Genetics, Inc. belongs?

Seattle Genetics, Inc. operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in Seattle Genetics, Inc. stocks?

In order to invest in Seattle Genetics, Inc. (SGEN) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers; TUKYSA, or tucatinib, for the treatment of certain metastatic human epidermal growth factor receptor 2 (HER2) -positive breast and colorectal cancers, and TIVDAK, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers. It is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Its programs including ADCETRIS, PADCEV and TIVDAK, are based on the Company’s antibody-drug conjugate (ADC) technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.